Youcare Pharmaceutical Group Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Youcare Pharmaceutical Group is forecast to grow earnings and revenue by 26.2% and 10.5% per annum respectively. EPS is expected to grow by 26.2% per annum. Return on equity is forecast to be 10.5% in 3 years.
Wichtige Informationen
26.2%
Wachstumsrate der Gewinne
26.2%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 19.3% |
| Wachstumsrate der Einnahmen | 10.5% |
| Zukünftige Eigenkapitalrendite | 10.5% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 31 Aug 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Keine Aktualisierungen
Recent updates
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 5,306 | 459 | N/A | 656 | 2 |
| 12/31/2025 | 4,735 | 381 | N/A | 518 | 2 |
| 12/31/2024 | 4,267 | 301 | N/A | 346 | 2 |
| 9/30/2024 | 4,230 | 242 | 377 | 720 | N/A |
| 6/30/2024 | 3,946 | 96 | 116 | 540 | N/A |
| 3/31/2024 | 4,036 | 169 | 232 | 714 | N/A |
| 12/31/2023 | 4,196 | 185 | 288 | 785 | N/A |
| 9/30/2023 | 3,998 | 152 | -164 | 393 | N/A |
| 6/30/2023 | 4,813 | 402 | -19 | 494 | N/A |
| 3/31/2023 | 4,770 | 357 | -350 | 129 | N/A |
| 12/31/2022 | 4,542 | 335 | -669 | -121 | N/A |
| 9/30/2022 | 5,123 | 507 | -299 | 212 | N/A |
| 6/30/2022 | 4,763 | 473 | -229 | 218 | N/A |
| 3/31/2022 | 4,987 | 539 | 138 | 490 | N/A |
| 12/31/2021 | 4,966 | 545 | 315 | 515 | N/A |
| 9/30/2021 | 4,879 | 562 | 550 | 702 | N/A |
| 6/30/2021 | 4,789 | 523 | 591 | 735 | N/A |
| 3/31/2021 | 4,481 | 476 | 509 | 638 | N/A |
| 12/31/2020 | 4,339 | 442 | 571 | 698 | N/A |
| 9/30/2020 | 4,096 | 358 | 412 | 498 | N/A |
| 12/31/2019 | 4,288 | 285 | 177 | 325 | N/A |
| 12/31/2018 | 3,983 | 268 | 19 | 193 | N/A |
| 12/31/2017 | 2,700 | 162 | N/A | 215 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 688658's forecast earnings growth (26.2% per year) is above the savings rate (2.9%).
Ertrag vs. Markt: 688658's earnings (26.2% per year) are forecast to grow faster than the CN market (25.8% per year).
Hohe Wachstumserträge: 688658's earnings are expected to grow significantly over the next 3 years.
Einnahmen vs. Markt: 688658's revenue (10.5% per year) is forecast to grow slower than the CN market (14% per year).
Hohe Wachstumseinnahmen: 688658's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 688658's Return on Equity is forecast to be low in 3 years time (10.5%).